Clinical trial
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB…
NCT00006215 · Amgen, Industry · Unknown status
Key facts
| NCT number | NCT00006215 |
|---|---|
| Title | Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma |
| Lead sponsor | Amgen, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, docetaxel, vinorelbine tartrate |
| Start date | Oct 1, 1999 |
| First posted | Mar 17, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: